Two-drug therapy for untreated minimal change disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new combination of two medicines (tacrolimus and ripertamab) for people with minimal change disease who have not been treated before. The goal is to see if this combination is safe and helps reduce protein in the urine and improve kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have minimal change disease (a kidney condition that causes protein to leak into urine) confirmed by a kidney biopsy, and this is your first treatment for it.
- You have heavy protein in your urine (more than 3.5 grams per day) and low albumin in your blood (below 30 grams per liter).
- Your kidney function is relatively good (eGFR of 60 or higher).
- You have not taken steroids or other immune-suppressing drugs for this condition before.
- You do not have current infections (like hepatitis B, C, or HIV) or a history of serious heart, brain, or other major diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
This trial tests a new drug called telitacicept in people with primary membranous nephropathy, a kidney condition that causes protein leakage in urine. It aims to see if the drug can reduce protein loss and protect kidney function, potentially slowing the disease's progression.
This study tests a new medicine called JMT601 for people with primary membranous nephropathy (a kidney condition causing protein leakage). The goal is to see if the medicine can reduce protein in the urine while being safe.
This trial tests an injected drug called BAT4406F for people with Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS), two types of kidney diseases that cause swelling and high protein in urine. It aims to see if the drug can help patients who have responded well to steroid therapy in the past.
Hear when a new Minimal Change Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.